Team

The Ally Bridge Group is led by a group of partners who have distinguished backgrounds and complementary experience in private equity, hedge fund, healthcare, finance, operations and management. Mr. Yu is the founder, CEO and CIO of the firm who carries a strong track record as an investment manager across multiple funds and strategies. Previously, Mr. Yu was Managing Director and Head of China Investments at Och-Ziff Capital Management (OZ), a leading global hedge fund, where he made some of OZ’s largest and highly successful investments. Prior to Och-Ziff, Mr. Yu was a Managing Director at Goldman Sachs in Hong Kong, where he headed several business units and played instrumental roles in some of the most important restructuring, IPO and M&A transactions of leading Chinese companies. Mr. Yu also advised leading global institutions on their China and Asia strategies and transactions. Before Goldman Sachs, Mr. Yu worked at Moody’s in New York, and then Credit Suisse in London and Hong Kong.

Since 2010, Mr. Yu has founded, launched and managed 4 funds covering venture, growth, buyout and hedge fund investing from China to U.S. to Europe.  Mr. Yu excels in originating and executing major investment themes such as global life science investing, which has become the primary focus of Mr. Yu and Ally Bridge, creating high-impact deals such as the landmark US$3.3 billion WuXi Pharmatech. He has expertise in cementing strategic transactions between emerging players and industry leaders, between companies in China, the U.S. and Europe, and helping global companies to access the China market while assisting Chinese companies to acquire novel technologies overseas.

  • Dr. Bin Li is a Partner and Managing Director of Ally Bridge Group as well as CEO & CIO of Ally Bridge LB Healthcare Fund. Dr. Li is involved in deal sourcing and post-investment value add to the ABG portfolio. Dr. Li joined ABG from Morgan Stanley where he was a Managing Director and the Head of Greater China Healthcare Research. Dr. Li was consistently ranked as the top analyst in Asia healthcare industry by various investor polls, including No.1 Asia healthcare analyst by the Institutional Investor for seven consecutive years (2009-2015), Wall Street Journal, Greenwich and Asia Money. Dr. Li brings both life science and finance expertise to ABG as he was educated as a biochemist and had worked at Merck Research Lab as a scientist before receiving an MBA and joining the equity research industry, where he spent 16 years as a healthcare equity research analyst at Merrill Lynch in the US before joining Morgan Stanley in Asia. He received his PhD in biochemistry and MBA from New York University and bachelor degree from Fudan University, China. Dr. Li brings a wealth of industry knowledge, analytics, expertise and network to the ABG team.
  • Anna Yaeger is the portfolio manager of ABG New York office and a Partner of ABG. She is responsible for managing US and European public equity positions managed by ABG. Ms. Yaeger has extensive experience in hedge fund portfolio management. Prior to ABG, Ms. Yaeger spent 12 years at SAC Capital/Point 72. She served as a Portfolio Manager for a $350 million long-short healthcare portfolio for 4 years and was a Senior Research Analyst for a healthcare portfolio prior to that. As a Portfolio Manager, she generated positive absolute and alpha returns for her fund every year. She invested in all sectors in the healthcare space across the US, Europe and Japan. Before joining SAC Capital/Point 72, Ms. Yaeger worked at Goldman Sachs in the Healthcare Investment Banking Group in New York. She graduated magna cum laude from The Wharton School at the University of Pennsylvania with a BS in Economics.
  • Dr. David Nikodem has over 12 years of investment experience as a seasoned investor with a global investment focus across all healthcare sectors. He has been responsible for portfolio construction, risk management and all portfolio decisions with Exane Asset Management in Paris (long/short global healthcare equities and long only European equities), BNP Paribas proprietary desk in New York, Blumberg Capital Management, LLC (long/short U.S. equity healthcare) and Senior Biotechnology Analyst with Orbitex Management Inc. and Acacia Research Investment Corporation. During this period, he managed a total of US$500 million of assets under management in New York and Paris and has accumulated significant experiences in identifying and valuing scientific technologies in healthcare and an in- depth understanding of both the U.S. and European healthcare industries. Dr. Nikodem has consistently picked stocks that generated favorable returns. Prior to healthcare investing, Dr. Nikodem had worked as a patent examiner in biotechnology with the United States Patent & Trademark Office and as a basic science researcher in National Institutes of Health. Dr. Nikodem holds a Ph.D. in Biochemistry and Molecular Biology from Georgetown University and a BA in Chemistry from The University of Virginia.
  • Charles Chon is a Partner and Managing Director of Ally Bridge Group. Mr. Chon leads ABG’s Medical Technologies effort and is a member of ABG’s Investment Committee. Before joining ABG in 2013, Mr. Chon had been a healthcare public equity research analyst for over 13 years on both buy-side and sell-side, mostly as Vice President and senior equity research analyst at Goldman Sachs on the US medical devices team. From there, Mr. Chon became the Sector Head for US medical devices research at Stifel Nicolaus. Mr. Chon began his career on Wall Street at ABN AMRO and also covered the healthcare sector from the buy-side at Fred Alger Management. Mr. Chon holds CFA designation, and received his MBA in healthcare management from Boston University and BA in Chemistry from Amherst College.
  • Andrew Pang began his career at Bank of America in London, where he was involved in a number of notable leveraged buyout transactions. Mr. Pang joined Ally Bridge Group in 2011 and was promoted to Principal in 2017. Before joining ABGs, Mr. Pang worked at Inter-Leader, a family-office investment group in Hong Kong, focusing on private equity transactions. He has developed excellent deal execution skills and experience working across different countries. In ABG, Mr Pang focuses on medical devices investments. Mr. Pang holds a BA in Mathematics and Computer Science from the University of Cambridge where he graduated with first class honours.
  • Reese Yeh has strong private equity investment experience across the Asia Pacific region. Ms. Yeh joined Ally Bridge Group in 2012 and was promoted to Principal in 2017. Prior to joining All Bridge Group, Ms. Yeh was with Morgan Stanley Private Equity Group for three years, focusing on the Group’s private equity transaction in Greater China and Southeast Asia. During her tenure with Morgan Stanley, Ms. Yeh developed excellent investing skill sets in due diligence, execution, and portfolio management. After joining ABG, Ms. Yeh has been focusing on investment in healthcare companies and provided value add to portfolio companies in many areas of finance. Ms. Yeh holds a BA in Business Administration in Finance from National Taiwan University.
  • Mr. Bigois started his career in 1997 in London at Wasserstein Perella then moved to the EMEA Healthcare banking groups of Credit Suisse and then Citi. He also worked as Chief Financial Officer of the US / France based specialty addiction disease biotechnology Company DrugAbuse Sciences. Mr. Bigois maintains an extensive and, global network of relationships and routinely executes advisory assignments with the western as well as selected emerging markets players. Mr. Bigois is a graduate of Ecole Centrale Paris (MSc Engineering) and holds an MSc in Finance and Economics of the London School of Economics (British council scholar).
  • Dr. Hong Zheng has over 10 years’ of experience in biotechnology, working across the fields of finance, industry and academia. Before joining Ally Bridge Group, Dr. Zheng was a senior equity research associate at Royal Bank of Canada capital markets, covering over 30 US biotech companies. Prior to RBC, Dr. Zheng was a medicinal chemist at Ra Pharmaceuticals for three years, where he led several drug discovery programs including small molecule and peptide drug candidates that later have entered into clinical stage. Dr. Zheng completed his Bachelor’s degree from Fudan University and received his PhD in Chemical Biology from Boston College, where he published many highly impactful research articles in top ranked journals as the first author.
  • Tinnie Chau joined Ally Bridge Group in 2015. Prior to joining ABG, Ms. Chau worked as a Manager at the Corporate Finance department of PwC, providing advisory services on M&A transactions. Ms. Chau graduated from the University of Cambridge with an M.A. in Biological Natural Sciences, specialized in Pathology and Microbiology. Ms. Chau is a CFA® charterholder.
  • Barney Han joined All Bridge Group in 2014. Previously, Mr. Han was a private equity investment analyst at LionRock, where he was involved in private equity investments with a particularly strong coverage of China related deals. Mr. Han is a CFA Level III and FRM II certification holder. Mr. Han holds an MSc in Finance from Hong Kong University as well as a BA in Economics from Nankai University.
  • Tony Ding, investment consultant of Ally Bridge LB Healthcare Fund, is responsible for investment research and analysis. Prior to joining Ally Bridge Group, he worked in Evalueserve, an outsourcing firm that provides healthcare research service for investment banks including Morgan Stanley. Mr. Ding is a CFA® charter holder. He graduated from Shanghai University with major in Management Information System then received his MBA degree from Pace University in New York. Mr. Ding speaks fluent Chinese and English.
  • Sam Tabar has 17 years in the fund management industry. He was recently partner to FullCycle, a sector-focused private equity fund. In this role, he was responsible for fundraising and operations. Before that, he was Head of Capital Strategy for Bank of America Merrill Lynch. In this role, he provided fund managers with targeted introductions to institutional investors such as endowments, foundations, pensions, fund of funds, and family offices. He also consulted on operations, legal, and also helped build back and front office teams. Before that, he was Co-Head of Marketing for Sparx Group, the largest independent fund in Asia Pacific. In this role, he worked and managed all facets of a global marketing effort. He started his career as an attorney for Skadden, Arps, Meagher, Slate & Flom with a focus on the fund industry. He graduated from Columbia Law School and received his BA (honors) from Oxford University. He was editor of the Columbia Business Law Journal and is currently a member of the New York State Bar.
  • Annie Lai, CFA and CPA, is the Group Chief Operating Officer and Chief Financial Officer. She has 20 years of experience in asset management and 4 years of experience in direct investment in China. Prior to joining ABG in April 2018, she was a Partner of Ward Ferry Management and served as the Chief Operating Officer, Chief Financial Officer and Chief Compliance Officer of the group. She spent over 13 years with Ward Ferry and had been instrumental in building the group's infrastructure and teams. During her time in Ward Ferry, she helped Ward Ferry navigate through significant regulatory and tax changes, market crisis and succession management. She is familiar with operational due diligence, SFC and SEC compliance matters. Previously, Annie was the Assistant Director of Finance at Lloyd George Management. Annie is a member of The Hong Kong Institute of CPAs, a CFA charterholder, and received her MBA from The Hong Kong University of Science and Technology.
  • Michael Sun, Chief Operating Officer of Ally Bridge LB Healthcare Fund, is responsible for fund operational matters including finance, accounting, tax and investor relationship. He has over 12 years’ of experience in financial service sector and is familiar with both U.S. and Asia investment and regulatory practices. Most recently Mr. Sun worked 6 years at FLAG Capital (acquired by Aberdeen Asset Management), a New York based multi-billion investment firm and he was leading a team of 7 as well as overseeing the Hong Kong branch’s back office operations. Mr. Sun contributed to FLAG Capital’s acquisition of a Hong Kong investment firm and led and accomplished the successful back-office transformation. He graduated from The George Washington University with a Master of Accountancy degree and received his bachelor degree in Economics from the Ocean University of China. Michael is currently a U.S. CPA as well as an AICPA member. Mr. Sun speaks fluent Chinese and English.
  • Amy Ko oversees the finance and administration function of ABG private equity funds. She has over 7 years of experience in private equity and fund administration. Prior to joining the ABG platform, Ms. Ko spent over 4 years (2011-2016) at CLSA Capital Partners, the Hong Kong-based private equity and venture capital arm of CLSA, specializing in growth companies, real estates and mid-market buyout. Ms. Ko started her career with the Financial Services practice of PricewaterhouseCoopers and subsequently worked with HSBC Fund Services in Hong Kong。 Ms. Ko holds the CPA designation, and received her MBA from the University of Hong Kong and a BBA in Accounting and Management of Organizations from the Hong Kong University of Science and Technology.
  • Mr. Boone, who had dedicated 28 years to Amgen, is one of the most accomplished drug discovery and development scientist in the biotech industry. As Global Head of Protein Science at Amgen, Mr. Boone led the successful development of several blockbuster biologic drugs including Neupogen, Neulasta and N-plate, in addition to his involvement in many other drugs successfully developed at Amgen. Apart from being a highly productive drug discovery scientist with strong biologic manufacturing expertise, Mr. Boone led and mentored a group of over 300 scientists at Amgen. His wealth of biotech knowledge, network and commercial successes are highly valuable to ABG’s investment effort in the biopharmaceutical field, especially in terms of in-depth due diligence and portfolio management.
  • Dr. Li, with over 30 years of experience in the life sciences sector, joins ABG from Pfizer (Boston) where he was Executive Director and Head of Biotherapeutic Technologies. Prior to Pfizer, Dr. Li spent over 18 years at Amgen in pharmaceuticals research and development. Prior to Pfizer, Dr, Li was in the academia, as a clinical professor at the Washington University School of Medicine. Throughout his career, Dr, Li advanced more than three dozen product candidates from discovery, preclinical, manufacturing to clinical development. Dr, Li holds an MD and MS in Pharmacology from Fujian Medical University.